摘要：

There is provided a monoclonal antibody that binds to a Her-2/neu receptor, and an IL-21 polypeptide or fragment of an IL-21 polypeptide as shown in SEQ ID NO:2 from amino acid residue 30 to residue 162, for use in treating cancer in a subject, wherein the subject has 1+ or 2+ overexpression levels of the Her-2/neu receptor

展开